CD38 and Miyoshi myopathy: Notably, the use of only 5 markers leaves room to analyse additional, pathology-related markers, according to the need to evaluate the presence of residual cells (e.g., in MM, CD38 and CD138 could be added and used to define and to verify the presence of plasma cells).